[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.66.254. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
June 9, 1999

Cost-effectiveness of Interferon Treatment for Hepatitis C

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;281(22):2083-2084. doi:10.1001/jama.281.22.2083

To the Editor: Dr Wong and colleagues1 examined the cost-effectiveness of management strategies for patients with chronic hepatitis C, and the authors concluded that a 12-week initial empirical trial of interferon alfa-2b is a "reasonable management strategy." Given a purported prevalence of some 4 million people in the United States infected with hepatitis C, of whom a significant number may have chronic hepatitis and be candidates for therapy, this is not a trivial recommendation.

First Page Preview View Large
First page PDF preview
First page PDF preview
×